Department of Pathology, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Korea.
Department of Urology, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Korea.
Investig Clin Urol. 2020 Mar;61(2):166-172. doi: 10.4111/icu.2020.61.2.166. Epub 2020 Feb 21.
As prostate cancer (PCa) is the second most commonly diagnosed cancer worldwide, finding novel markers for prognosis is crucial. BRCA1-associated protein 1 (BAP-1), a nuclear-localized deubiquitinating enzyme, has been reported in several human cancers. However, its prognostic role in PCa remains unknown. Herein, we assessed the prognostic and clinicopathologic significance of BAP-1 in PCa.
Seventy surgical specimens from radical prostatectomy cases were examined. Two cores per case were selected for construction of tissue microarrays (TMAs). After the exclusion of two cases because of tissue sparsity, BAP-1 immunohistochemical expression was evaluated in 68 cases of formalin-fixed, paraffin-embedded TMA tissue blocks. The immunohistochemical stain was scored according to proportion of nuclear staining: negative (<10% of tumor cells) or positive (≥10% of tumor cells).
BAP-1 expression was negative in 30 cases (44.1%) and positive in 38 cases (55.9%). Positive BAP-1 expression was more common in pT3b disease than in pT2 (p=0.038). A high preoperative prostate-specific antigen level was correlated with BAP-1 expression (p=0.014). Age, lymphovascular invasion, perineural invasion, and grade group were not significantly correlated with BAP-1 expression. Patients with positive BAP-1 expression showed significantly shorter disease-free survival (p=0.013). Additionally, BAP-1 was an independent prognostic factor of PCa (p=0.035; hazard ratio, 9.277; 95% confidence interval, 1.165-73.892).
Our study findings showed an association of BAP-1 expression with poor PCa prognosis and suggest a potential role for BAP-1 as a prognostic biomarker for PCa.
由于前列腺癌（PCa）是全球第二大常见的癌症，因此寻找新的预后标志物至关重要。BRCA1 相关蛋白 1（BAP-1）是一种核定位的去泛素化酶，已在几种人类癌症中报道。然而，其在 PCa 中的预后作用尚不清楚。在此，我们评估了 BAP-1 在 PCa 中的预后和临床病理意义。
对 70 例根治性前列腺切除术病例的手术标本进行了检查。每个病例选择两个核心用于构建组织微阵列（TMA）。排除了两个因组织稀疏的病例后，对 68 例福尔马林固定、石蜡包埋的 TMA 组织块进行了 BAP-1 免疫组织化学表达的评估。免疫组织化学染色根据核染色比例进行评分：阴性（<10%的肿瘤细胞）或阳性（≥10%的肿瘤细胞）。
BAP-1 表达阴性的有 30 例（44.1%），阳性的有 38 例（55.9%）。BAP-1 阳性表达在 pT3b 疾病中比在 pT2 中更为常见（p=0.038）。术前前列腺特异性抗原水平较高与 BAP-1 表达相关（p=0.014）。年龄、脉管侵犯、神经周围侵犯和分级组与 BAP-1 表达无显著相关性。BAP-1 阳性表达的患者疾病无进展生存率明显缩短（p=0.013）。此外，BAP-1 是 PCa 的独立预后因素（p=0.035；风险比，9.277；95%置信区间，1.165-73.892）。
我们的研究结果表明 BAP-1 表达与 PCa 的不良预后相关，并提示 BAP-1 可能作为 PCa 的预后生物标志物。
